From the Ground Up: Evolving Strategies in the Identification and Team-based Management of Patients with Early-Stage Alzheimer’s Disease Neurobiology
The care of Alzheimer’s disease (AD) is involved, multifaceted, and variable depending on individual patient preferences. With the introduction of novel tools and strategies for diagnosis and therapy, additional clinicians and responsibilities are being introduced into AD management each day. Though these developments are highly promising for patients, their integration is complicated by the wide breadth of providers in disparate practice locations/specialties that can be responsible for them. Without clarity on which elements fall under the umbrella of each provider or corresponding proficiency in the fulfillment of these elements, clinicians may fail to effectively implement key components of care, allowing patients to fall through the cracks.
To help correct for such oversights and ensure comprehensive care, the proposed activity series is designed to help delineate and address the different modern roles in the current management of AD across clinical specialties. By exploring individual roles and their effective execution, providers involved in AD can more confidently and proficiently ensure that their patients are receiving complete and optimal care.
This activity is intended for general practice and internal medicine physicians, neurologists, geriatricians, radiologists, psychiatrists, advanced practice professionals, registered nurses, and pharmacists involved in the diagnosis and management of Alzheimer’s disease.
Part 1: Suspicion, Identification, and Evaluation of Patients Who May Have Early Alzheimer's Disease Neurobiology
- Recognize subtle clinical indicators of early cognitive impairment and their distinction from age-related cognitive decline to more effectively identify appropriate candidates for formal cognitive testing
- Appraise the utility of available clinical assessment scales in evaluating mild cognitive impairment (MCI) and the implications of their results to ensure patients are optimally evaluated and started on the best care path
Part 2: Importance and Implications of Biomarkers in Diagnosis and Modern Treatment of Alzheimer's Disease
- Define the clinical uses of AD biomarker analyses (e.g., CSF, PET, serum), including both their diagnostic and therapeutic implications, to better streamline and individualize patient management
- Evaluate patient selection for and phase 3 data with new and emerging amyloid-targeting therapies to determine how and for whom their approvals may impact the team-based approach to AD management
Part 3: Evolving Roles in Alzheimer's Disease Management: Team-based Care in the Modern Age of Disease-Modifying Therapy
- Outline optimal strategies for allocation of team resources, delineation of care roles, and communication between disciplines across the spectrum of AD management in order to maximize clinic flow and patient outcomes
This activity is jointly provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development (Purdue) and Efficient LLC.
Conflicts of Interest Disclosure Policy:
To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.
All relevant conflicts of interest have been mitigated prior to the start of the activity.
None of the planners, reviewers, Efficient, LLC staff, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.